Disease landscape

DLBCL clinical trials

Get alerts when DLBCL trials change

368 active trials 204 recruiting 37 Phase 3 192 sponsors 35 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 31 of 35 changes on 19 trials

2026-08-06
Primary completion pushed: 2039-12-01 → 2041-12-01
Primary endpoint(s) modified
Trial sites expanded: 5 → 11 locations
Completion pushed: 2039-12-01 → 2041-12-01
NCT06116110 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · Miltenyi Biomedicine GmbH
2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or… · Jonsson Comprehensive Cancer Center · Phase 1
2026-08-08
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2028-06-30 → 2029-06-30
NCT06486051 A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell… · Malaghan Institute of Medical Research · Phase 2
2026-07-31
Primary completion pushed: 2030-01-15 → 2030-04-30
Recruitment opened
Trial sites expanded: 1 → 34 locations
Completion pushed: 2030-01-15 → 2030-04-30
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large… · Universität Münster · Phase 2
2026-08-20
Sponsor changed: Mwanasha Merrill, MD → Carrie Ho, MD
Primary completion pushed: 2028-07-31 → 2028-08-31
Completion pushed: 2029-07-31 → 2029-08-31
NCT07588698 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma · Carrie Ho, MD · Phase 2
2026-08-14
Recruitment opened
NCT07570823 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and… · Sinocelltech Ltd. · Phase 3
2026-07-31
Recruitment opened
NCT07609862 A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · Guangzhou Lupeng Pharmaceutical Company LTD. · Phase 1/2
2026-08-26
Recruitment opened
NCT06594939 Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly… · Medical College of Wisconsin · Phase 2
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT07078500 Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB… · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2
2026-07-31
Recruitment opened
Trial sites expanded: 2 → 6 locations
NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers · Ascentage Pharma Group Inc. · Phase 1
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT06464861 Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT07669194 Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large… · Second Affiliated Hospital, School of Medicine, Zhejiang University
2026-08-22
Enrollment closed, study ongoing
NCT04231877 Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the… · University of Washington · Phase 1
2026-08-21
Trial sites expanded: 172 → 178 locations
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… · Regeneron Pharmaceuticals · Phase 3
2026-08-07
Trial sites expanded: 168 → 172 locations
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… · Regeneron Pharmaceuticals · Phase 3
2026-08-14
Trial sites expanded: 9 → 17 locations
NCT06980116 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell… · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Phase 1
2026-08-01
Completion moved earlier: 2030-12-31 → 2029-12-31
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) · Janssen Research & Development, LLC · Phase 3
2026-08-22
Completion pushed: 2026-07-01 → 2027-06-02
NCT03150329 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · City of Hope Medical Center · Phase 1
2026-08-12
Completion pushed: 2026-07-16 → 2027-07-16
NCT03220022 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and… · National Cancer Institute (NCI) · Phase 1
2026-08-12
Completion pushed: 2026-04 → 2029-09
NCT02889523 Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma… · The Lymphoma Academic Research Organisation · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07788118 A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell… Second Affiliated Hospital, Zhejiang University, School of Medicine new Phase 1/2
2026-08-24 NCT07782944 CD38 Targeted -PET/ CT for Multiple Myeloma Guilin Medical University, China new
2026-08-18 NCT07771361 BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma… Luminary Therapeutics new Phase 2
2026-08-14 NCT07764601 R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma WEI XU new
2026-08-06 NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL… Vitruviae new Phase 1/2
2026-08-06 NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… Natera, Inc. new
2026-08-05 NCT07748364 Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Joshua Brody new Phase 2
2026-07-31 NCT07739654 Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. King Edward Medical University new Phase 3
2026-07-27 NCT07729397 Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma… The Methodist Hospital Research Institute new Phase 1
2026-07-24 NCT07725406 Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Weill Medical College of Cornell University new Phase 1

Active trials by phase

Early Phase 1
8
Phase 1
69
Phase 1/2
48
Phase 2
139
Phase 2/3
7
Phase 3
30
Phase 4
2
Not charted: 65 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 368

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT05518383 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting 2022-08-26
NCT07760610 Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After… The First Hospital of Jilin University Not Yet Recruiting 2026-08-12
Phase 3
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… Merck Sharp & Dohme LLC Recruiting 2026-08-21
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… Regeneron Pharmaceuticals Recruiting 2026-08-20
NCT06792253 Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory… BeBetter Med Inc Recruiting 2026-08-19
NCT07570823 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and… Sinocelltech Ltd. Recruiting 2026-08-13
NCT07739654 Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. King Edward Medical University Recruiting 2026-08-10
NCT07188558 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy Lyell Immunopharma, Inc. Recruiting 2026-08-04
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Janssen Research & Development, LLC Recruiting 2026-07-31
NCT07409428 A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory… Hutchmed Recruiting 2026-07-20
NCT06929624 A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse… Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2026-07-01
NCT04094311 Study of Out of Specification for Tisagenlecleucel Novartis Pharmaceuticals Recruiting 2026-06-25
NCT07493109 Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially… Ou Bai, MD/PHD Recruiting 2026-03-25
NCT06220032 Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With… Stichting Hemato-Oncologie voor Volwassenen Nederland Recruiting 2026-01-05
NCT07011056 A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse… Chengdu Zenitar Biomedical Technology Co., Ltd Recruiting 2025-09-19
NCT04332822 A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With… Nordic Lymphoma Group Recruiting 2024-09-19
NCT06522555 The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de… Ruijin Hospital Recruiting 2024-08-05
NCT06521255 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With… Beijing InnoCare Pharma Tech Co., Ltd. Recruiting 2024-07-25
NCT04442412 Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by… Fondazione Italiana Linfomi - ETS Recruiting 2022-08-26
NCT02443077 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or… National Cancer Institute (NCI) Active, Not Recruiting 2026-07-31
NCT04404283 Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of… Seagen, a wholly owned subsidiary of Pfizer Active, Not Recruiting 2026-07-22
NCT04408638 A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs… Hoffmann-La Roche Active, Not Recruiting 2026-07-07
NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB… Acerta Pharma BV Active, Not Recruiting 2026-06-25
NCT07220187 Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter… SWOG Cancer Research Network Not Yet Recruiting 2026-06-11
NCT04628494 A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… Genmab Active, Not Recruiting 2026-05-22
See all 368 active DLBCL trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (18) · Ruijin Hospital (17) · City of Hope Medical Center (14) · Sun Yat-sen University (10) · Memorial Sloan Kettering Cancer Center (9) · Genmab (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Mayo Clinic (6) · Fondazione Italiana Linfomi - ETS (5) · Institute of Hematology & Blood Diseases Hospital, China (5)

Get alerts when DLBCL trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free